News

Tri-party agreement will drive biotech innovation via integrated lab-to-market collaboration L’Oréal Groupe today announces a tri-party agreement with biotech innovator, Abolis Biotechnologies and global specialty manufacturer, Evonik, to enable the discovery, development and manufacturing of innovative and sustainable ingredients for beauty products and beyond.

L’Oréal has been recognized for its commitment to diversity, equity and inclusion, securing the fifth position globally in this year’s prestigious FTSE Diversity & Inclusion Index Top 100 companies list.

Every year, L'Oréal's Annual Report offers a deep dive into the heart of our strategy, our commitments, and our ambitions for the future.

Every year, L'Oréal's Annual Report offers a deep dive into the heart of our strategy, our commitments, and our ambitions for the future.

Test your knowledge on L'Oréal Group, its brands, its initiatives and its financial, social and environmental performance by exploring the latest edition of our annual report! CLICK HERE TO TAKE THE SUMMER QUIZTo find out more about the beauty of performance, discover the 2023 Annual Report.

Inside informationL’ORÉAL GROUPE ACQUIRES A 10% STAKE IN GALDERMA, THE PURE-PLAY DERMATOLOGY LEADER AND ONE OF THE WORLD’S LARGEST PLAYERS IN INJECTABLE AESTHETICS.

L’Oréal announces that it has made available to the public and filed with the Autorité desmarchés financiers its half-year financial report as of June 30, 2024.

Continued Strong Growth and Market OutperformanceFurther Operating Margin Improvement Sales: 22.

This page is dedicated to all items relating to the 2024 Half-Year Results.